Bernard H. Bochner, MD, FACS
Urologic Surgeon
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Bladder Cancer
- Kidney Cancer
- Urinary Diversion and Reconstruction
Meet Urologic Surgeon Bernard Bochner
Video DetailsAbout Me
- Sir Murray F. Brennan Chair in Surgery
I am a urologic surgeon who specializes in surgery for men and women with cancers of the genitourinary system. Examples of the specific tumors that I treat include cancers of the bladder, prostate, kidney, and testis.
My main areas of expertise include radical surgical procedures for invasive bladder cancer and reconstructive surgery of the urinary system following radical cystectomy or pelvic exenteration. Removal of the bladder, also called radical cystectomy, serves as the standard for definitive treatment of high-risk bladder tumors and can provide a cure in the majority of patients with early, invasive lesions. Function-sparing procedures (including preservation of the nerves responsible for erectile function and advanced reconstructive techniques that re-create the natural urination pathway after bladder removal) can also be performed to provide an excellent postoperative quality of life.
Read more
I am actively involved in clinical and translational research to determine which treatments are most likely to maximize a patient’s chances of a cure. I am involved in ongoing studies to determine which features of a tumor predict for more or less aggressive behavior. This will help us individualize treatment for each patient based on his or her tumor’s characteristics. I am very interested in and actively study ways to improve patients’ quality of life after surgery.
I joined the Memorial Sloan Kettering faculty in 2000. I serve as the coordinator of the bladder cancer multidisciplinary working group and am co-director of the pelvic reconstruction/surgery group at Memorial Sloan Kettering. I am actively involved in urologic oncology at the national level, serving as faculty for postgraduate courses in urologic oncology for the American Urological Association. I am involved in many professional societies including the American Urological Association, the Society of Urologic Oncology, and the Society of University Surgeons. I am on several editorial boards and serve as reviewer for a variety of urology-related journals.
A urologic surgeon is a doctor with special training in surgery on the genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) (GU) system. This includes the bladder, kidney, penis, prostate, and testicles.
My Specialties
- Bladder Cancer
- Kidney Cancer
- Urinary Diversion and Reconstruction
- Nerve-Sparing Surgical Techniques
- Genitourinary Sarcomas
Education
- MD, University of California at Los Angeles
Residencies
- Surgery - University of Southern California School of Medicine
- Urology - University of Southern California School of Medicine
Awards and Honors
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2018-2020)
Fellowships
- Urologic Oncology - University of Southern California/Norris Comprehensive Cancer Center
Board Certifications
- Urology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Bochner sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Bochner
- A Phase I Study of 2141-V11 Immunotherapy in People with Non-Muscle Invasive Bladder Cancer that Did Not Respond to Standard Treatment
- Clinical Trials Co-Investigated by Dr. Bochner
- A Phase 3 Study Comparing Intravesical BCG with Intravesical Docetaxel and Gemcitabine for Non-Muscle Invasive Bladder Cancer
- A Phase I/II Study Assessing the Addition of Gemcitabine to BCG Treatment in People with High-Grade Non-Muscle Invasive Bladder Cancer that Returned after Prior BCG
- A Phase II Study of Chemotherapy without Surgery in Patients with Muscle-Invasive Bladder Cancer and Certain Gene Mutations
Read more
- A Phase II Study of Enfortumab Vedotin and Pembrolizumab Immunotherapy Given Before Surgery in People with Bladder Cancer
- A Phase II Study of Oral Erdafitinib in People with Recurrent Non-Invasive Bladder Cancer
- A Pilot Study Assessing Immunotherapy with Nivolumab Alone or with Ipilimumab Before Surgery for Patients with Muscle-invasive Bladder Cancer Who Cannot Have Cisplatin-Based Chemotherapy
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Bochner’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Bernard H. Bochner discloses the following relationships and financial interests:
-
Olympus
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].